{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:25:30Z","timestamp":1793849130962,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.clinthera.2026.06.024","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:33:00Z","timestamp":1785756780000},"page":"1142-1150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database"],"prefix":"10.1016","volume":"48","author":[{"given":"Ximin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyin","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangwei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirou","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huancun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2211-7895","authenticated-orcid":false,"given":"Yuting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.06.024_bib0001","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3390\/biomedicines13061319","article-title":"The precision-guided use of PI3K pathway inhibitors for the treatment of solid malignancies","volume":"13","author":"Schmitz","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0002","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and safety of PI3K inhibitors in cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch Toxicol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI180927","article-title":"USP10\/GSK3\u03b2-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer","volume":"135","author":"Kumari","year":"2025","journal-title":"J Clin Investig"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/10781552251350959","article-title":"Efficacy and safety of phosphoinositide 3-kinase inhibitors and AKT-inhibitors in combination with fulvestrant in PIK3CA mutated, HR-positive, HER2-negative invasive breast cancer: a systematic review","author":"Larck","year":"2025","journal-title":"J Oncol Pharm Pr"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ejh.14065","article-title":"Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed\/refractory chronic lymphocytic leukemia: a Swedish nation-wide real-world report on consecutively identified patients","volume":"111","author":"Mattsson","year":"2023","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0006","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3Kdelta-selective and PI3Kalpha\/delta-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0007","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1002\/cpt.3173","article-title":"Model-based benefit\/risk analysis for the copanlisib intermittent dosing regimen","volume":"115","author":"Morcos","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0008","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.3324\/haematol.2024.285043","article-title":"The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: final analysis including overall survival","volume":"109","author":"Danilov","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0009","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/bcp.15143","article-title":"Adverse events of alpelisib: a postmarketing study of the World Health Organization pharmacovigilance database","volume":"88","author":"Chen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0010","article-title":"Efficacy and safety of copanlisib in relapsed\/refractory B-cell non-Hodgkin lymphoma: a meta-analysis of prospective clinical trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0011","article-title":"Safety and efficacy of dual PI3K-delta, gamma inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: a systematic review and meta-analysis of prospective clinical trials","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0012","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2540","article-title":"Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper","volume":"37","author":"Cuneo","year":"2019","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0013","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1007\/s00210-025-04721-8","article-title":"Biological sex differences in pharmacokinetics and adverse drug reactions","volume":"399","author":"Aljohmani","year":"2026","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","article-title":"Sex differences in pharmacokinetics predict adverse drug reactions in women","volume":"11","author":"Zucker","year":"2020","journal-title":"Biol Sex Differ"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071054","article-title":"Sex-related differences in immunotherapy toxicities: insights into dimorphic responses","volume":"17","author":"Canzian","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0016","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1038\/s41598-025-88838-z","article-title":"Analysis of ADR reports of cetuximab based on the FDA adverse event reporting system database","volume":"15","author":"Zhao","year":"2025","journal-title":"Sci rep"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1438292","article-title":"Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS","volume":"15","author":"Xu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0018","article-title":"A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0019","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA adverse event reporting system (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0021","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0022","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0023","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0024","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijcard.2020.06.032","article-title":"Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: a real-world experience","volume":"320","author":"Akhtar","year":"2020","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0025","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12938-021-00973-6","article-title":"The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019","volume":"21","author":"Yao","year":"2022","journal-title":"Biomed Eng Online"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0026","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-019-0799-1","article-title":"Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study","volume":"12","author":"Zhou","year":"2019","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0027","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13060179","article-title":"Sex differences in immune responses to infectious diseases: the role of genetics, hormones, and aging","volume":"13","author":"Rio","year":"2025","journal-title":"Diseases"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2025.112630","article-title":"The sex-chromosomes related cellular dimorphism in physiology and pathology","volume":"608","author":"Antinozzi","year":"2025","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0029","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0030","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/eji.70069","article-title":"Loss of PI3Kdelta activity drives autoimmune colitis by impairing extrathymic TREG differentiation","volume":"55","author":"Lim","year":"2025","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0032","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/14740338.2023.2243220","article-title":"Gender differences in adverse events related to Osimertinib: a real-world pharmacovigilance analysis of FDA adverse event reporting system","volume":"23","author":"Li","year":"2024","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0033","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Br Bioinform"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101425","article-title":"Risk of hepatitis B virus reactivation following treatment with abatacept: a retrospective study of international pharmacovigilance databases","volume":"48","author":"Wang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0035","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40264-023-01366-5","article-title":"Patient-reported reasons for antihypertensive medication change: a quantitative study using social media","volume":"1","author":"Micale","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.06.024_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40264-024-01473-x","article-title":"Caveats of covariate adjustment in disproportionality analysis for best practices","volume":"48","author":"Noguchi","year":"2025","journal-title":"Drug Saf"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826002390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:35:34Z","timestamp":1793846134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826002390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":36,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0149291826002390"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-Specific Safety Profiles of PI3K Inhibitors: A Real-World Pharmacovigilance Study Based on FAERS Database","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.06.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}